Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Blois, France Clinical Trials

A listing of Blois, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

The combination of venetoclax (V) and ibrutinib (I) has recently emerged as a very effective therapy in both relapse and front-line settings. The preliminary results of the CLARITY (R/R CLL) and CAPTIVATE (untreated CLL) studies have demonstrated the promising potential of the I+VEN combination, which led to a very high …

Phase

0.0 miles

Learn More »

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

Standard management of castration-resistant metastatic prostate cancer is represented by chemotherapy with Docetaxel 75 mg/m every 3 weeks combined with Prednisone since a symptomatic and overall survival benefit was demonstrated. Although this benefit is independent of age in the study by Tannock (cut-off:69), it does not seem possible to extrapolate …

Phase

0.0 miles

Learn More »

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group. PREVENE (PREemptive VENEtoclax) trial.

Phase

0.0 miles

Learn More »

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

The purpose of the OPTIPRIME phase II non-randomised study is to evaluate the efficacy and tolerability of the combination of FOLFOX plus panitumumab according to a "stop and go" strategy. If disease control is achieved while on induction treatment, oxaliplatin and panitumumab will be stopped after the sixth cycle; a …

Phase

2.05 miles

Learn More »

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

AAV is a group of potentially life-threatening autoimmune diseases. Preclinical data demonstrate that primed neutrophils are activated by ANCA and generate C5a that engages C5a receptors on neutrophils. Patients with ANCA-related disease have elevated plasma and urine levels of C5a in active disease but not in remission. IFX-1 is as …

Phase

9.23 miles

Learn More »